229 related articles for article (PubMed ID: 24844072)
1. Court rules generic drug companies not responsible for adverse outcomes.
Kouros N
Monash Bioeth Rev; 2013 Sep; 31(2):23-4. PubMed ID: 24844072
[No Abstract] [Full Text] [Related]
2. On access and accountability--two Supreme Court rulings on generic drugs.
Boumil MM; Curfman GD
N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
[No Abstract] [Full Text] [Related]
3. Lawsuits anticipated on generic biologicals front.
Fox JL
Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
[No Abstract] [Full Text] [Related]
4. The Supreme Court, preemption, and malpractice liability.
Kesselheim AS; Studdert DM
N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
[No Abstract] [Full Text] [Related]
5. Good law from tragic facts--Congress, the FDA, and preemption.
Annas GJ
N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
[No Abstract] [Full Text] [Related]
6. PLIVA v. Mensing: generic consumers' unfortunate hand.
Lee SB
Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
[No Abstract] [Full Text] [Related]
7. Why doctors should worry about preemption.
Curfman GD; Morrissey S; Drazen JM
N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269
[No Abstract] [Full Text] [Related]
8. The National Childhood Vaccine Injury Act and the supreme court's interpretation.
Blake V
Virtual Mentor; 2012 Jan; 14(1):31-4. PubMed ID: 23116914
[No Abstract] [Full Text] [Related]
9. The FDA, preemption, and the Supreme Court.
Glantz LH; Annas GJ
N Engl J Med; 2008 May; 358(18):1883-5. PubMed ID: 18450601
[No Abstract] [Full Text] [Related]
10. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
Boumil MM; Curfman G
JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167
[No Abstract] [Full Text] [Related]
11. Generics still unable to resolve ANDA patent issues by declaratory judgment, but is a supreme court resolution on the way?
Eccleston LE
Health Care Law Mon; 2006 Dec; ():3-5. PubMed ID: 17236678
[No Abstract] [Full Text] [Related]
12. Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers.
Rostron A
Duke Law J; 2011 Feb; 60(5):1123-91. PubMed ID: 21365961
[TBL] [Abstract][Full Text] [Related]
13. Path to approval proves rocky for copycat biodrugs.
Wadman M
Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
[No Abstract] [Full Text] [Related]
14. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety.
Kesselheim AS
Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322
[TBL] [Abstract][Full Text] [Related]
15. Merck v. Integra: Supreme Court permits use of patented compounds to obtain Food and Drug Administration approvals.
Manthei JR; Hathaway CR; Grant MA; Chung DD
Food Drug Law J; 2006; 61(2):273-7. PubMed ID: 16903032
[No Abstract] [Full Text] [Related]
16. The impact of Wyeth v. Levine on FDA regulation of prescription drugs.
Ausness RC
Food Drug Law J; 2010; 65(2):247-83, i-ii. PubMed ID: 24475542
[TBL] [Abstract][Full Text] [Related]
17. Supreme Court rules in favor of 'pay-for-delay' settlements.
Sklan A
Pharm Pat Anal; 2013 Sep; 2(5):582-3. PubMed ID: 24386654
[No Abstract] [Full Text] [Related]
18. Impossible? Outlawing state safety laws for generic drugs.
Glantz LH; Annas GJ
N Engl J Med; 2011 Aug; 365(8):681-3. PubMed ID: 21830958
[No Abstract] [Full Text] [Related]
19. Risk, responsibility, and generic drugs.
Kesselheim AS; Avorn J; Greene JA
N Engl J Med; 2012 Nov; 367(18):1679-81. PubMed ID: 23113477
[No Abstract] [Full Text] [Related]
20. FDA: approval of generic drug reversed by U.S. Court of Appeals.
Beliveau S
J Law Med Ethics; 2002; 30(1):120-2. PubMed ID: 11905262
[No Abstract] [Full Text] [Related]
[Next] [New Search]
